RAD — Radiopharm Theranostics Income Statement
0.000.00%
Last trade - 00:00- AU$48.41m
- AU$10.78m
- AU$0.30m
- 17
- 22
- 52
- 22
Annual income statement for Radiopharm Theranostics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0.292 | 0.299 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 0.485 | 21 | 34.8 | 47.5 |
| Operating Profit | -0.485 | -21 | -34.5 | -47.2 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.485 | -30.4 | -34.6 | -47.9 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.485 | -30.4 | -34.6 | -47.9 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.485 | -30.4 | -34.6 | -47.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.485 | -30.4 | -34.6 | -47.9 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.002 | -0.153 | -0.107 | -0.124 |
| Special Dividends per Share |